by AdoloreJTC24 | May 21, 2024 | Press Releases
Development program for the treatment of osteoarthritis (OA) chronic knee pain is fully funded through the first-in-human clinical study by a UG3/UH3 grant awarded by NIH/NINDS HEAL programOngoing progress with IND-enabling studies of ADLR-1001 gene therapy for the...
by AdoloreJTC24 | May 16, 2024 | Press Releases
Findings highlight the advantages of Adolore’s approach for the delivery of proprietary gene therapy directly to specialized pain-sensing peripheral nerves (nociceptors) that mediate profound analgesia with the potential to address the great unmet need for...
by AdoloreJTC24 | Mar 4, 2024 | Press Releases
Patent and CA8* gene therapy technology licensed by Adolore BioTherapeutics from the University of MiamiCompany advancing development of rdHSV-CA8* gene therapy for the treatment of chronic osteoarthritis (OA) knee pain toward an INDDELRAY BEACH, FL / March 4, 2024 /...
by AdoloreJTC24 | Feb 7, 2024 | Uncategorized
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
by AdoloreJTC24 | Jan 30, 2024 | Press Releases
DELRAY BEACH, FL / January 30, 2024 / Adolore BioTherapeutics (“Adolore” or the “Company”), a biotechnology company focused on developing breakthrough opioid-free gene therapy treatments for chronic pain, today announced that Roy C. Levitt, MD,...